41 Smith, Phase II Metabolism, UNC Chapel Hill, 8/2012 UGT PolymorphismTo date, deficient conjugation with bilirubin which leads to severe disease (Crigler Najar) or elevated bilirubin (Gilberts syndrome) have been identified
daily Tesamorelin, if selected) Weeks 2-12 Optimization Phase Bi-weekly nurse calls for dose tweaks and side-effect checks Nutrition & strength-training plan synced to peptide cycle Months 3-12 Progress & Maintenance Quarterly labs, DXA scans, and sleep-quality assessments Option to stack with GLP-1, lipotropics, or IV nutrient therapy 7
Combining these two can compound GI distress, making it harder to distinguish which agent is responsible and potentially reducing tolerability and compliance
Worth Trying or Not
Activating two important hormone pathwaysGLP-1 and GIP receptorscan also reduce appetite and support weight loss in some individuals
Variants in GIPR, MC4R, and FTO can influence peptide response potential, though they do not determine outcomes